SCHEMBL4526264

SCHEMBL4526264

O=C(Cc1ccccc1Cl)Nc1onc(-c2cccc3c2OCO3)c1-c1ccncc1

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.54
PRKACA P17612 1/20 0.43
ROCK1 Q13464 1/20 0.43
ROCK2 O75116 1/20 0.43
MAPK9 P45984 1/20 0.42
MAPK10 P53779 1/20 0.42
MAPK11 Q15759 1/20 0.42
GHSR Q92847 1/20 0.39
RIPK3 Q9Y572 1/20 0.39
HSP90AA1 P07900 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1874970 0.90 MAPK14 (0.67) MAPK14PRKACAROCK1ROCK2MAPK9
SCHEMBL4337023 0.89 MAPK14 (0.61) MAPK14PRKACAROCK1ROCK2RIPK3
SCHEMBL4332759 0.84 MAPK14 (0.61) MAPK14MAPK9MAPK10MAPK11HSP90AA1
SCHEMBL4465470 0.84 MAPK14 (0.64) MAPK14MAPK9MAPK10MAPK11
SCHEMBL4341320 0.84 MAPK14 (0.61) MAPK14ROCK2MAPK9MAPK10MAPK11
SCHEMBL4339299 0.83 MAPK14 (0.60) MAPK14MAPK9MAPK10MAPK11HSP90AA1
SCHEMBL4342438 0.83 MAPK14 (0.60) MAPK14MAPK9MAPK10MAPK11HSP90AA1
SCHEMBL4336216 0.83 MAPK14 (0.59) MAPK14ROCK2MAPK9MAPK10MAPK11
SCHEMBL4343996 0.83 MAPK14 (0.61) MAPK14PRKACAROCK1MAPK9MAPK10
SCHEMBL4337029 0.81 MAPK14 (0.57) MAPK14ROCK1ROCK2MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885PRKACA 118/4885ROCK1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.